A report on a class of drugs known as GLP-1 agonists — Ozempic, Munjaro and zep bounda report was submitted to the Food and Drug Administration (FDA) stating that patients experienced hair loss, depression, and a respiratory complication called aspiration, to name a few.
6 products manufactured by novo nordisk They were included in the list of drugs being evaluated by the FDA. When asked for comment, the company said it “supports the safety and efficacy of all of our GLP-1RA medicines” and is cooperating with the FDA as it conducts its evaluation.
These drugs mimic a hormone known as GLP-1, which stimulates insulin production, slows stomach emptying, and reduces appetite.Most of these drugs are approved for treatment type 2 diabetes Things like Wegovy are approved, but weight loss management.
Eli Lilly and Co., whose products are also named under evaluation by the FDA, issued an open letter Thursday warning people not to take the company's GLP-1 agonists to: “Cosmetics” purpose.
Eli Lilly is the maker of the type 2 diabetes drug Mounjaro and the recently approved weight loss drug Zepbound, both of which are a form of tirzepatide.
“Mounjaro and Zepbound are indicated for the treatment of serious diseases. They are not approved for, and should not be used for, cosmetic weight loss,” the company said.
The company also warned against ingesting it. imitation productsaid the substances were tested and found to contain “significant amounts of impurities,” and in some cases the imitations were found to be simply sugar alcohols.
